UK markets close in 4 hours 43 minutes
  • FTSE 100

    6,968.37
    +28.79 (+0.41%)
     
  • FTSE 250

    22,446.72
    +91.27 (+0.41%)
     
  • AIM

    1,247.57
    +3.66 (+0.29%)
     
  • GBP/EUR

    1.1518
    +0.0021 (+0.19%)
     
  • GBP/USD

    1.3780
    -0.0001 (-0.01%)
     
  • BTC-GBP

    45,417.82
    -888.22 (-1.92%)
     
  • CMC Crypto 200

    1,367.91
    -7.87 (-0.57%)
     
  • S&P 500

    4,124.66
    -16.93 (-0.41%)
     
  • DOW

    33,730.89
    +53.62 (+0.16%)
     
  • CRUDE OIL

    62.81
    -0.34 (-0.54%)
     
  • GOLD FUTURES

    1,746.00
    +9.70 (+0.56%)
     
  • NIKKEI 225

    29,642.69
    +21.70 (+0.07%)
     
  • HANG SENG

    28,793.14
    -107.69 (-0.37%)
     
  • DAX

    15,253.80
    +44.65 (+0.29%)
     
  • CAC 40

    6,225.16
    +16.58 (+0.27%)
     

Valneva Announces Supervisory Board Changes

  • Oops!
    Something went wrong.
    Please try again later.
VALNEVA
·4-min read
  • Oops!
    Something went wrong.
    Please try again later.

Saint-Herblain (France), March 13, 2021Valneva SE (“Valneva”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that MVM Partner Thomas Casdagli has stepped down from Valneva’s Supervisory Board on March 12, 2021.

“It has been a pleasure to work with Valneva over the last few years and be a part of the fantastic progress in the Lyme, chikungunya and, more recently, COVID-19 programs. I feel that it is time for me to step aside to make space for a new member of the Supervisory Board, with US Listed company experience, as Valneva takes the next steps in its journey. I wish the company every success in the future,” said MVM Partner Thomas Casdagli.

Thomas Lingelbach, Chief Executive Officer of Valneva, added, “I would like to thank Thomas and MVM Partners for the great contributions and support given to Valneva since first investing in 2016. We continue to execute on our strategy and will strengthen further our Supervisory Board in due course.”

Further to MVM’s investment in Valneva in 2016, MVM had a right to appoint a Supervisory Board member. This right has now lapsed.

About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, as well as our established vaccine development capabilities, to develop prophylactic vaccines to address these diseases. We have leveraged our expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Valneva Investor and Media Contacts
Laetitia Bachelot-Fontaine
Director Investor Relations & Corporate Communications
M +33 (0)6 4516 7099
investors@valneva.com



Teresa Pinzolits
Corporate Communications Specialist
T +43 (0)1 20620 1116
communications@valneva.com

Valneva Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing and completion of research, development and clinical trials for product candidates, the ability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of their in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Attachment